Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial
- PMID: 28457980
- DOI: 10.1016/S2352-3026(17)30077-7
Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial
Erratum in
-
Correction to Lancet Haematol 2017; 4: e258-71.Lancet Haematol. 2017 Jun;4(6):e257. doi: 10.1016/S2352-3026(17)30084-4. Lancet Haematol. 2017. PMID: 28583287 No abstract available.
Abstract
Background: Effective treatment of trauma-induced coagulopathy is important; however, the optimal therapy is still not known. We aimed to compare the efficacy of first-line therapy using fresh frozen plasma (FFP) or coagulation factor concentrates (CFC) for the reversal of trauma-induced coagulopathy, the arising transfusion requirements, and consequently the development of multiple organ failure.
Methods: This single-centre, parallel-group, open-label, randomised trial was done at the Level 1 Trauma Center in Innsbruck Medical University Hospital (Innsbruck, Austria). Patients with trauma aged 18-80 years, with an Injury Severity Score (ISS) greater than 15, bleeding signs, and plasmatic coagulopathy identified by abnormal fibrin polymerisation or prolonged coagulation time using rotational thromboelastometry (ROTEM) were eligible. Patients with injuries that were judged incompatible with survival, cardiopulmonary resuscitation on the scene, isolated brain injury, burn injury, avalanche injury, or prehospital coagulation therapy other than tranexamic acid were excluded. We used a computer-generated randomisation list, stratification for brain injury and ISS, and closed opaque envelopes to randomly allocate patients to treatment with FFP (15 mL/kg of bodyweight) or CFC (primarily fibrinogen concentrate [50 mg/kg of bodyweight]). Bleeding management began immediately after randomisation and continued until 24 h after admission to the intensive care unit. The primary clinical endpoint was multiple organ failure in the modified intention-to-treat population (excluding patients who discontinued treatment). Reversal of coagulopathy and need for massive transfusions were important secondary efficacy endpoints that were the reason for deciding the continuation or termination of the trial. This trial is registered with ClinicalTrials.gov, number NCT01545635.
Findings: Between March 3, 2012, and Feb 20, 2016, 100 out of 292 screened patients were included and randomly allocated to FFP (n=48) and CFC (n=52). Six patients (four in the FFP group and two in the CFC group) discontinued treatment because of overlooked exclusion criteria or a major protocol deviation with loss of follow-up. 44 patients in the FFP group and 50 patients in the CFC group were included in the final interim analysis. The study was terminated early for futility and safety reasons because of the high proportion of patients in the FFP group who required rescue therapy compared with those in the CFC group (23 [52%] in the FFP group vs two [4%] in the CFC group; odds ratio [OR] 25·34 [95% CI 5·47-240·03], p<0·0001) and increased needed for massive transfusion (13 [30%] in the FFP group vs six [12%] in the CFC group; OR 3·04 [0·95-10·87], p=0·042) in the FFP group. Multiple organ failure occurred in 29 (66%) patients in the FFP group and in 25 (50%) patients in the CFC group (OR 1·92 [95% CI 0·78-4·86], p=0·15).
Interpretation: Our results underline the importance of early and effective fibrinogen supplementation for severe clotting failure in multiple trauma. The available sample size in our study appears sufficient to make some conclusions that first-line CFC is superior to FFP.
Funding: None.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Comment in
-
Putting a stop to exsanguination.Lancet Haematol. 2017 Jun;4(6):e245. doi: 10.1016/S2352-3026(17)30082-0. Lancet Haematol. 2017. PMID: 28583282 No abstract available.
-
Early fibrinogen-concentrate administration in management of trauma-induced coagulopathy.Lancet Haematol. 2017 Aug;4(8):e348. doi: 10.1016/S2352-3026(17)30125-4. Lancet Haematol. 2017. PMID: 28754193 No abstract available.
Similar articles
-
Variations and obstacles in the use of coagulation factor concentrates for major trauma bleeding across Europe: outcomes from a European expert meeting.Eur J Trauma Emerg Surg. 2022 Apr;48(2):763-774. doi: 10.1007/s00068-020-01563-2. Epub 2021 Jan 5. Eur J Trauma Emerg Surg. 2022. PMID: 33399876 Free PMC article. Review.
-
The role of four-factor prothrombin complex concentrate in coagulopathy of trauma: A propensity matched analysis.J Trauma Acute Care Surg. 2018 Jul;85(1):18-24. doi: 10.1097/TA.0000000000001938. J Trauma Acute Care Surg. 2018. PMID: 29664892
-
French lyophilized plasma versus fresh frozen plasma for the initial management of trauma-induced coagulopathy: a randomized open-label trial.J Thromb Haemost. 2018 Mar;16(3):481-489. doi: 10.1111/jth.13929. Epub 2018 Jan 22. J Thromb Haemost. 2018. PMID: 29274254 Clinical Trial.
-
iTACTIC - implementing Treatment Algorithms for the Correction of Trauma-Induced Coagulopathy: study protocol for a multicentre, randomised controlled trial.Trials. 2017 Oct 18;18(1):486. doi: 10.1186/s13063-017-2224-9. Trials. 2017. PMID: 29047413 Free PMC article. Clinical Trial.
-
[Therapy of trauma-induced coagulopathy - what is the evidence?].Anasthesiol Intensivmed Notfallmed Schmerzther. 2012 Sep;47(9):528-39; quiz 540. doi: 10.1055/s-0032-1325284. Epub 2012 Sep 11. Anasthesiol Intensivmed Notfallmed Schmerzther. 2012. PMID: 22968981 Review. German.
Cited by
-
Long-Term Safety Analysis of a Fibrinogen Concentrate (RiaSTAP®/Haemocomplettan® P).Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241254106. doi: 10.1177/10760296241254106. Clin Appl Thromb Hemost. 2024. PMID: 38803191 Free PMC article. Review.
-
Revolutionizing trauma care: advancing coagulation management and damage control anesthesia.Anesth Pain Med (Seoul). 2024 Apr;19(2):73-84. doi: 10.17085/apm.24038. Epub 2024 Apr 30. Anesth Pain Med (Seoul). 2024. PMID: 38725162 Free PMC article. Review.
-
Changes in coagulation factor XIII activity during resuscitation for hemorrhagic shock.J Rural Med. 2024 Apr;19(2):76-82. doi: 10.2185/jrm.2023-028. Epub 2024 Apr 12. J Rural Med. 2024. PMID: 38655226 Free PMC article.
-
Resuscitative adjuncts and alternative products when blood supplies are limited.Trauma Surg Acute Care Open. 2024 Apr 15;9(Suppl 2):e001415. doi: 10.1136/tsaco-2024-001415. eCollection 2024. Trauma Surg Acute Care Open. 2024. PMID: 38646035 Free PMC article. No abstract available.
-
Hemostatic effect of fibrinogen concentrate on traumatic massive hemorrhage: a propensity score matching study.Trauma Surg Acute Care Open. 2024 Jan 30;9(1):e001271. doi: 10.1136/tsaco-2023-001271. eCollection 2024. Trauma Surg Acute Care Open. 2024. PMID: 38298819 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical